Modular nanotransporters containing Keap1 monobodies are capable of reducing the toxic effect of acetaminophen on the liver of mice

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Previously, we created a modular nanotransporter (MNT) containing a monobody to Keap1, an intracellular protein inhibitor of the Nrf2 transcription factor that controls cellular protection from oxidative stress and is capable of interacting with Keap1 in hepatocytes and protect this cells from the effects of hydrogen peroxide. Oxidative liver damage by acetaminophen was used as a model to study the antitoxic effect of this MNT. Intraperitoneal injection of acetaminophen to mice resulted in an increase in the level of alanine aminotransferase and aspartate aminotransferase in the blood, as well as in liver edema. A significant decrease in the level of these enzymes in the blood, along with a decrease in liver edema, was observed after preliminary intravenous administration of MNT 2 hours before the acetaminophen injection. The results obtained can serve as a basis for creating drugs aimed at treating diseases associated with oxidative stress.

About the authors

Yu. V. Khramtsov

Institute of Gene Biology, RAS

Moscow, Russian Federation

A. A. Rosenkranz

Institute of Gene Biology, RAS; Lomonosov Moscow State University

Moscow, Russian Federation; Moscow, Russian Federation

A. V. Ulasov

Institute of Gene Biology, RAS

Moscow, Russian Federation

T. A. Slastnikova

Institute of Gene Biology, RAS

Moscow, Russian Federation

T. N. Lupanova

Institute of Gene Biology, RAS

Moscow, Russian Federation

R. T. Alieva

Institute of Gene Biology, RAS

Moscow, Russian Federation

G. P. Georgiev

Institute of Gene Biology, RAS

Moscow, Russian Federation

A. S. Sobolev

Institute of Gene Biology, RAS; Lomonosov Moscow State University

Email: alsobolev@yandex.ru
Moscow, Russian Federation; Moscow, Russian Federation

References

  1. Bellezza I., Giambanco I., Minelli A., et al. // Acta Mol. Cell Res. 2018. V. 1865(5). P. 721–733.
  2. Hayes J.D., Dinkova-Kostova A.T. // Trends Biochem. Sci. 2014. V. 39(4). P. 199–218.
  3. Ulasov A.V., Rosenkranz A.A., Georgiev G.P., et al. // Life Sci. 2022. V. 291. 120111.
  4. Robledinos-Anton N., Fernandez-Gines R., Manda G., et al. // Oxid. Med. Cell Longev. 2019. V. 2019. 9372182.
  5. Ngo V., Duennwald M.L. // Antioxidants. (Basel). 2022. V. 11(12).
  6. Taguchi K., Kensler T.W. // Arch. Pharm. Res. 2020. V. 43(3). P. 337–349.
  7. Patra U., Mukhopadhyay U., Sarkar R., et al. // Antivir. Res. 2019. V. 161. P. 53–62.
  8. Olagnier D., Farahani E., Thyrsted J., et al. // Nat. Commun. 2020. V. 11. 4938.
  9. Khramtsov Y.V., Ulasov A.V., Slastnikova T.A., et al. // Pharmaceutics. 2023. V. 15. 2687.
  10. Khramtsov Y.V., Ulasov A.V., Rosenkranz A.A., et al. // Pharmaceutics. 2024. V. 16. 1345.
  11. Lee W.M. // Hepatol. 2017. V. 67. P. 1324–1331.
  12. McGill M.R., Williams C.D., Xie Y., et al. // Toxicol. Appl. Pharmacol. 2012. V. 264. P. 387–394.
  13. Vorobyeva A., Bragina O., Altai M., et al. // Contrast. Media Mol. Imaging. 2018. V. 2018. 6930425.
  14. Steffens M. G., Kranenborg M.H., O.C. Boerman O.C., et al. // Cancer Biother. Radiopharm. 1998. V. 13. P. 133–139.
  15. Ferris T., Carroll L., Jenner S., et al. // J. Labelled Comp Radiopharm. 2021. V. 64. P. 92–108.
  16. Bruinstroop E., van der Spek A.H., Boelen A. // Eur. Thyroid J. 2023. V. 12. e220211.
  17. Dohan O., De la Vieja A., Paroder V., et al. // Endocr. Rev. 2003. V. 24. P. 48–77.
  18. Shen Z., Wang Y., Su Z., et al. // Chem. Biol. Interact. 2018. V. 282. P. 22–28.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Russian Academy of Sciences

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).